Sars-cov2 antibodies and methods of use thereof
AssigneeInvivyd, Inc.
InventorsLaura Walker, Anna Wec, Robert Allen, Brandyn West, Daniel Chupp
Life of this patent
Estimating the term…
Loading patent…
AssigneeInvivyd, Inc.
InventorsLaura Walker, Anna Wec, Robert Allen, Brandyn West, Daniel Chupp
Estimating the term…
The present disclosure is directed to antibodies and antigen binding fragments thereof, having improved binding specificity for coronaviruses, such as SARS-CoV-2, including neutralizing antibodies. Other embodiments contemplate using anti-CoV-S antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with coronaviruses or the S protein thereof and conditions where neutralization or inhibition of coronaviruses or the S protein thereof would be therapeutically beneficial.
An isolated antibody, or antigen-binding fragment thereof, which specifically binds to the spike protein of a coronavirus (“CoV-S”), wherein said antibody, or antigen-binding fragment thereof, comprises a heavy chain variable region (VH) comprising a VH CDR1 comprising SEQ ID NO:
A method of treating or preventing infection by SARS-CoV, SARS-CoV-2, and/or another coronavirus in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an antibody, or antigen-binding fragment thereof, which specifically binds to a spike protein of the coronavirus,
Dependencies are inferred from the claim text.